ImmunAdd Inc.

Startup

Found in 2022, ImmunAdd is a privately held biotech pharmaceutical company focused on the design of vaccine adjuvant and formulation development of vaccines. Our team members have accumulated years of experience in medicinal chemistry, drug formulation, drug regulations, biological animal evaluations, and clinical trials.

QS-21, a golden standard saponin adjuvant, has been approved by the FDA in the formulation of shingle vaccine, malaria vaccine, RSV vaccine, and Covid vaccine. With the promising immune responses in vaccines, Quillaja harvesting is currently unsustainable. In addition, QS-21’s widespread use is limited by its structural instability, dose-limiting toxicity, and the low-yielding nature of the purification processes.

Introducing IA-05, our innovative saponin-based adjuvant that represents a refined QS-21 analog. IA-05 exhibits enhanced tolerability, stability, and the ability to elicit long-term immune responses when combined with a variety of antigens, including viral and bacterial vaccines. One of the key advantages of IA-05 is its cost-effective large-scale manufacturing process, which eliminates the need for Quillaja harvesting. This positions IA-05 as a viable solution to meet the global demand for vaccine commercialization. Furthermore, IA-05 holds great potential for advancing the development of immunotherapies and therapeutic vaccines, facilitating new avenues in the field of immunology. Join us in transforming the future of healthcare with IA-05!